Press Releases | Friday, Sep 13, 2024 - Genentech
FDA approves Ocrevus Zunovo™, the first twice-a-year 10-minute subcutaneous injection for relapsing and progressive multiple sclerosis, offering more treatment options based on individual needs.
Reference News
Roche's Genentech unit announces FDA approval of Ocrevus Zunovo, a twice-yearly subcutaneous injection for relapsing and primary progressive multiple sclerosis, based on phase 3 trial data showing comparable safety and efficacy to the intravenous formulation.
Genentech received FDA approval for Ocrevus Zenovo, a twice-a-year subcutaneous injection for treating relapsing and primary progressive multiple sclerosis.
Multiple Sclerosis is a debilitating central nervous system disease with varied courses and symptoms among individuals.
FDA approves Ocrevus Zunovo™, a twice-a-year, 10-minute subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options based on individual needs.
The FDA approved Roche's Ocrevus Zunovo, an under-the-skin injection for multiple sclerosis, expanding treatment options to centers unable to administer the IV version. The 10-minute injection, given twice a year, targets CD20-positive B cells and is based on a study showing no significant difference in Ocrevus levels when administered subcutaneously.
FDA approves Ocrevus Zunovo™, the first twice-a-year 10-minute subcutaneous injection for relapsing and progressive multiple sclerosis, offering more treatment options based on individual needs.
FDA approves Ocrevus Zunovo™, a twice-a-year, 10-minute subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options.